An anonymous director reports
AETERNA ZENTARIS ANNOUNCES CLOSING OF $12 MILLION PUBLIC OFFERING
Aeterna Zentaris Inc. has closed its previously announced public offering of 17,544,516 units at a price to the public of 45 cents per unit and 9,122,150 prefinanced units at a price to the public of 44.99 cents per prefinanced unit. Each unit sold in this offering contains one common share and one common warrant to purchase one common share. Each pre-funded unit sold in this offering contains one pre-funded warrant to purchase one common share at an exercise price of $0.0001 per share and one common warrant to purchase one common share. The gross proceeds to the Company from the offering totaled approximately $12 million, before deducting placement agent fees and offering expenses.
H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
Each common share warrant has an exercise price of $0.45 per share, is exercisable immediately and will expire five years from the date of issuance. Each pre-funded warrant is exercisable immediately until all other pre-funded warrants have been exercised.
The Company intends to use the net proceeds of this offering for general corporate purposes, which includes, among other purposes, the funding of a pediatric clinical trial in the E.U. and U.S. for Macrilen (macimorelin), the investigation of further therapeutic uses of macimorelin and the expansion of pipeline development activities.
The securities described above were offered by Aeterna Zentaris pursuant to an effective registration statement on Form F-1 (File No. 333-232935) which was previously declared effective by the U.S. Securities and Exchange Commission ("SEC") on July 1, 2020.
The offering was made only by means of a prospectus forming part of the effective registration statement. The terms of the offering were disclosed in a final prospectusfiled by Aeterna Zentaris with the SEC and may be obtained at the SEC's website. Electronic copies of the final prospectus may also be obtained by contacting H.C. Wainwright & Co., LLC, 430 Park Avenue, 3rd Floor, New York, NY 10022, by telephone at 646-975-6996 or by email at
In obtaining the approval of the Toronto Stock Exchange of the offering, the Company relied on the exemption set forth in Section 602.1 of the TSX Company Manual available to "Eligible lnterlisted Issuers", since the Company's common shares are also listed on the NASDAQ Capital Market and had less than 25% of the overall trading volume of its listed securities occurring on all Canadian marketplaces in the twelve months immediately preceding the date on which application was made to TSX to approve the offering.
About Aeterna Zentaris Inc.
Aeterna Zentaris is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company's lead product, Macrilen (macimorelin), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Macrilen is currently marketed in the United States through a license agreement with Novo Nordisk and Aeterna Zentaris receives double-digit royalties on sales. Aeterna Zentaris owns all rights to macimorelin outside of the U.S. and Canada.
Aeterna Zentaris is also leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of child-onset growth hormone deficiency (CGHD), an area of significant unmet need.
We seek Safe Harbor.
© 2021 Canjex Publishing Ltd. All rights reserved.